Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

134 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Melphalan 180 mg/m2 can be safely administered as conditioning regimen before an autologous stem cell transplantation (ASCT) in multiple myeloma patients with creatinine clearance 60 mL/min/1.73 m2 or lower with use of palifermin for cytoprotection: results of a phase I trial.
Abidi MH, Agarwal R, Ayash L, Deol A, Al-Kadhimi Z, Abrams J, Cronin S, Ventimiglia M, Lum L, Zonder J, Ratanatharathorn V, Uberti J. Abidi MH, et al. Among authors: deol a. Biol Blood Marrow Transplant. 2012 Sep;18(9):1455-61. doi: 10.1016/j.bbmt.2012.03.010. Epub 2012 Mar 24. Biol Blood Marrow Transplant. 2012. PMID: 22453252 Free PMC article. Clinical Trial.
Anti-thymocyte globulin (thymoglobulin), tacrolimus, and sirolimus as acute graft-versus-host disease prophylaxis for unrelated hematopoietic stem cell transplantation.
Al-Kadhimi Z, Gul Z, Rodriguez R, Chen W, Smith D, Mitchell A, Abidi M, Ayash L, Deol A, Lum L, Forman S, Ratanatharathorn V, Uberti J. Al-Kadhimi Z, et al. Among authors: deol a. Biol Blood Marrow Transplant. 2012 Nov;18(11):1734-44. doi: 10.1016/j.bbmt.2012.06.004. Epub 2012 Jun 16. Biol Blood Marrow Transplant. 2012. PMID: 22710143 Free PMC article.
Phase I trial of bortezomib during maintenance phase after high dose melphalan and autologous stem cell transplantation in patients with multiple myeloma.
Abidi MH, Gul Z, Abrams J, Ayash L, Deol A, Ventimiglia M, Lum L, Mellon-Reppen S, Al-Kadhimi Z, Ratanatharathorn V, Zonder J, Uberti J. Abidi MH, et al. Among authors: deol a. J Chemother. 2012 Jun;24(3):167-72. doi: 10.1179/1973947812Y.0000000004. J Chemother. 2012. PMID: 22759762 Free PMC article. Clinical Trial.
A phase I dose-escalation trial of high-dose melphalan with palifermin for cytoprotection followed by autologous stem cell transplantation for patients with multiple myeloma with normal renal function.
Abidi MH, Agarwal R, Tageja N, Ayash L, Deol A, Al-Kadhimi Z, Abrams J, Cronin S, Ventimiglia M, Lum L, Ratanatharathorn V, Zonder J, Uberti J. Abidi MH, et al. Among authors: deol a. Biol Blood Marrow Transplant. 2013 Jan;19(1):56-61. doi: 10.1016/j.bbmt.2012.08.003. Epub 2012 Aug 11. Biol Blood Marrow Transplant. 2013. PMID: 22892551 Free PMC article. Clinical Trial.
CD20-targeted T cells after stem cell transplantation for high risk and refractory non-Hodgkin's lymphoma.
Lum LG, Thakur A, Liu Q, Deol A, Al-Kadhimi Z, Ayash L, Abidi MH, Pray C, Tomaszewski EN, Steele PA, Schalk DL, Yano H, Mitchell A, Dufresne M, Uberti JP, Ratanatharathorn V. Lum LG, et al. Among authors: deol a. Biol Blood Marrow Transplant. 2013 Jun;19(6):925-33. doi: 10.1016/j.bbmt.2013.03.010. Epub 2013 Mar 22. Biol Blood Marrow Transplant. 2013. PMID: 23529012 Free PMC article. Clinical Trial.
134 results